

Handbook of
Psychopharmacology

Volume 17

Biochemical Studies
of CNS Receptors

Edited by
Leslie L. Iversen
Susan D. Iversen
and Solomon H. Snyder

Volume 17

Biochemical Studies of CNS Receptors

Edited by

Leslie L. Iversen

*Department of Pharmacology
University of Cambridge*

Susan D. Iversen

*Department of Psychology
University of Cambridge*

and

Solomon H. Snyder

*Departments of Neuroscience, Pharmacology, and Psychiatry
The Johns Hopkins University
School of Medicine*

PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

Main entry under title:

Biochemical studies of CNS receptors.

(Handbook of psychopharmacology; v. 17)

Includes bibliographical references and index.

1. Neurotransmitter receptors. 2. Drug receptors. 3. Neurochemistry. I. Iversen, Leslie Lars. II. Iversen, Susan D., 1940 — . III. Snyder, Solomon H., 1938 — . IV. Title: Biochemical studies of C.N.S. receptors. V. Series. [DNLM: 1. Receptors, Sensory. 2. Central nervous system—Physiology. 3. Central nervous system—Drug effects. 4. Receptors, Drug. QV 77 H236 sect. 4 v. 17]

QP364.7.B56 1983

612'.82

82-22376

ISBN 0-306-41145-8

© 1983 Plenum Press, New York

A Division of Plenum Publishing Corporation

233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

Handbook of Psychopharmacology

SECTION I: BASIC NEUROPHARMACOLOGY

- Volume 1 Biochemical Principles and Techniques in Neuropharmacology
- Volume 2 Principles of Receptor Research
- Volume 3 Biochemistry of Biogenic Amines
- Volume 4 Amino Acid Neurotransmitters
- Volume 5 Synaptic Modulators
- Volume 6 Biogenic Amine Receptors

SECTION II: BEHAVIORAL PHARMACOLOGY IN ANIMALS

- Volume 7 Principles of Behavioral Pharmacology
- Volume 8 Drugs, Neurotransmitters, and Behavior
- Volume 9 Chemical Pathways in the Brain

SECTION III: HUMAN PSYCHOPHARMACOLOGY

- Volume 10 Neuroleptics and Schizophrenia
- Volume 11 Stimulants
- Volume 12 Drugs of Abuse
- Volume 13 Biology of Mood and Antianxiety Drugs
- Volume 14 Affective Disorders: Drug Actions in Animals and Man

SECTION IV: BASIC NEUROPHARMACOLOGY: AN UPDATE

- Volume 15 New Techniques in Psychopharmacology
- Volume 16 Neuropeptides
- Volume 17 Biochemical Studies of CNS Receptors

Handbook of
Psychopharmacology

Volume 17

Biochemical Studies of CNS Receptors

CONTRIBUTORS

CLAUS BRAESTRUP, *Research Laboratories, A/S Ferrosan, DK-2860 Soeborg, Denmark; and Skt. Hans Mental Hospital, DK-4000 Roskilde, Denmark*

IAN CREESE, *Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, California 92093*

FREDERICK J. EHLERT, *Department of Pharmacology, University of Arizona Health Sciences Center, Tucson, Arizona 85724*

G. FILLION, *Pharmacology Department, Pasteur Institute, 75015 Paris, France*

JACK PETER GREEN, *Department of Pharmacology, Mount Sinai School of Medicine, The City University of New York, New York, New York 10029*

MARK W. HAMBLIN, *Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, California 92093*

HANS W. KOSTERLITZ, *Unit for Research on Addictive Drugs, University of Aberdeen, Marischal College, Aberdeen AB9 1AS, Scotland*

STUART E. LEFF, *Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, California 92093*

MOGENS NIELSEN, *Psychopharmacological Research Laboratories, Department E, Skt. Hans Mental Hospital, DK-4000 Roskilde, Denmark*

STEWART J. PATERSON, *Unit for Research on Addictive Drugs, University of Aberdeen, Marischal College, Aberdeen AB9 1AS, Scotland*

LINDA E. ROBSON, *Unit for Research on Addictive Drugs, University of Aberdeen, Marischal College, Aberdeen AB9 1AS, Scotland*

WILLIAM R. ROESKE, *Department of Internal Medicine, University of Arizona Health Sciences Center, Tucson, Arizona 85724*

DAVID R. SIBLEY, *Department of Neurosciences, University of California, San Diego, School of Medicine, La Jolla, California 92093*

S. ROBERT SNODGRASS, *Department of Neurology, University of Southern California, Children's Hospital of Los Angeles, Los Angeles, California 90027*

SOLOMON H. SNYDER, *Departments of Neuroscience, Pharmacology, and Experimental Therapeutics, and Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University of Medicine, Baltimore, Maryland 21205*

HENRY I. YAMAMURA, *Departments of Pharmacology, Psychiatry, and Biochemistry, University of Arizona Health Sciences Center, Tucson, Arizona 85724*

PREFACE

It is now eight years since the first *Handbook* volumes on Basic Neuropharmacology were published, and there have been many important advances. As in many other areas in science, progress in this field has depended to a considerable extent on the availability of new experimental methods, and Volume 15 reviews some major recent developments, including new autoradiographic techniques that allow direct visualization of drug and transmitter receptors in the nervous system, and the pinpointing of the precise locations of the changes in brain metabolism elicited by various drug treatments. Volume 16 and 17 cover two of the most active areas for basic research in psychopharmacology at the moment: the characterization of drug and transmitter receptors in brain by radioligand binding techniques, and studies of the role of small peptides in brain function. The latter area, in particular, illustrates how rapidly progress continues to be made in basic research on the mechanisms of chemical communication within the nervous system. Eight years ago when the *Handbook* first appeared none of the opioid peptides (enkephalins and endorphins) had yet been identified. Since then a whole new area of basic biological research has focused on these substances, and in addition we know of more than thirty other neuropeptides with putative CNS transmitter functions.

We hope that these new volumes will help to keep the *Handbook of Psychopharmacology* abreast of the most recent advances in the field, and continue to make it a valuable reference work for all who are involved in research in this increasingly active field of science. The response to earlier volumes has been remarkably positive, and we remain indebted to the publishers for conceiving the original idea, and to the many contributors who have labored long and hard to bring it to fruition.

L.L.I.
S.D.I.
S.H.S.

CONTENTS

CHAPTER 1

Molecular Aspects of Neurotransmitter Receptors: An Overview

SOLOMON H. SNYDER

1. Introduction	1
2. Receptor Recognition: Ion and Nucleotide Regulation Associated with "Second Messengers"	3
3. Solubilized and Purified Receptors Clarify Synaptic Mechanisms	6
4. Neurotransmitter Uptake Receptors	8
5. References	10

CHAPTER 2

Opiate Receptors

LINDA E. ROBSON, STEWART J. PATERSON,

AND HANS W. KOSTERLITZ

1. Introduction	13
2. Scope and Limitations of Methods	14
2.1. Pharmacological Methods <i>in Vitro</i> and <i>in Vivo</i>	14
2.2. Biochemical Methods; Binding Assays <i>in Vivo</i> and <i>in Vitro</i>	15
2.3. Histochemical Methods	17
3. Heterogeneity of Opiate Receptors	17
3.1. Evidence Based on Pharmacological Assays	17
3.2. Binding Assays	22
3.3. Selective Protection Assays	31
3.4. Effects of Irreversible Agonists and Antagonists ..	33
4. Distribution of Opiate Receptors	35
4.1. Central Nervous System	35

4.2.	Peripheral Nervous System	40
4.3.	Cultured Cells	42
4.4.	Subcellular Distribution	44
4.5.	Ontogenetic and Phylogenetic Variations	44
5.	Properties of the Opiate Binding Sites	46
5.1.	Physicochemical Properties	46
5.2.	Effects of Ions	48
5.3.	Effects of Nucleotides	50
6.	Isolation of Opiate Receptors	52
6.1.	Inactive Ligand-Macromolecular Complexes	52
6.2.	Solubilized Macromolecules to Which Opioid Ligands Bind	55
7.	Assessment of the Pharmacological and Binding Properties of Narcotic Analgesic Drugs	56
8.	Excitation Effector Coupling	60
9.	Changes in Binding Sites Induced by Drugs or Pathological Conditions	64
10.	References	67

CHAPTER 3

CNS Dopamine Receptors

IAN CREESE, MARK W. HAMBLIN, STUART E. LEFF,
AND DAVID R. SIBLEY

1.	Introduction	81
2.	Dopaminergic Agonists and Antagonists and Their Actions	82
3.	Anatomy	85
4.	Pharmacological Characterization of Dopamine Receptors	87
4.1.	The "D-1" Dopamine Receptor and the Dopamine-Sensitive Adenylate Cyclase	87
4.2.	"D-2" Dopamine Receptors	89
5.	Dopamine Receptors in the Pituitary	90
6.	Dopamine Receptors in the Striatum	97
6.1.	Studies with Competitive Ligands	99
7.	Irreversible Modification of Dopamine Receptors	104
7.1.	Phenoxybenzamine: Selective Alkylation of [³ H]- Butyrophenone Binding Sites	105
7.2.	N-Chloroethylnorapomorphine: Effects on [³ H]- NPA Binding and Dopamine-Receptor-Mediated Behavior	107
7.3.	Heat Treatment: Multiple Effects Mimicking GTP	109
8.	Solubilization and Isolation of Dopamine Receptors	111

9.	Neuroanatomical Localization of Dopamine Receptors in the CNS	112
9.1.	Neostriatum	114
9.2.	Substantia Nigra	118
9.3.	Retina	119
10.	Regulation of Dopamine Receptors	121
10.1.	Up Regulation	121
10.2.	Down Regulation	124
11.	Concluding Comments	125
12.	References	126

CHAPTER 4

5-Hydroxytryptamine Receptors in Brain

G. FILLION

1.	Introduction	139
2.	Serotonergic Recognition Sites in the CNS	141
2.1.	Neuronal Binding Sites	142
2.2.	Glial Binding Sites	145
2.3.	Multiple Serotonin Receptors	145
3.	5-HT-Sensitive Adenylate Cyclase	150
3.1.	Neuronal 5-HT-Sensitive Adenylate Cyclase	151
3.2.	Glial 5-HT-Sensitive Adenylate Cyclase	152
4.	Mechanism of Regulation of Serotonin Receptors	153
4.1.	Regulation at the Binding Site	153
4.2.	Regulation of 5-HT-Sensitive Adenylate Cyclase Activity	155
4.3.	Proposed Mechanism of Regulation of the 5-HT Receptor	156
4.4.	Effects of Antidepressant Drugs on the Postsynaptic Serotonin Receptor	158
5.	Conclusions	159
6.	References	160

CHAPTER 5

Receptors for Amino Acid Transmitters

S. ROBERT SNODGRASS

1.	Introduction	167
1.1.	Historical Review	168
1.2.	Definitions	169
1.3.	Neurophysiological Techniques	170

1.4.	Radioligand Binding Studies	171
1.5.	Isolated Tissue or Organ Techniques	174
2.	GABA Receptors	175
2.1.	Historical Review	175
2.2.	Separation of GABA Receptors from Uptake	176
2.3.	GABA Agonists	178
2.4.	GABA Antagonists	184
2.5.	Coupling of GABA Receptors to Cyclic Nucleotides	187
2.6.	Presynaptic GABA Receptors	188
2.7.	Unusual Responses to GABA	190
2.8.	Other GABA-Related Drugs	191
2.9.	GABA Receptor Autoradiography	196
2.10.	Complex Interactions between GABA, Benzodiazepines, and Barbiturates	196
2.11.	Developmental Studies of GABA Receptors	200
2.12.	Desensitization	201
2.13.	GABA Agonists and Seizures	202
2.14.	GABA Receptors and Human Disease	203
2.15.	Radioreceptor Assays	205
3.	Glycine Receptors	205
3.1.	Historical Review	205
3.2.	Glycine Effects and Glycine Agonists	206
3.3.	Glycine Antagonists	206
3.4.	Glycine Receptor Autoradiography	207
3.5.	Absence of Desensitization at Glycine Synapses ...	208
4.	Other "Inhibitory Amino Acids"	208
5.	Excitatory Amino Acids	209
6.	Summary	217
7.	References	218

CHAPTER 6

The Nature of Muscarinic Receptor Binding

FREDERICK J. EHLERT, WILLIAM R. ROESKE,
AND HENRY I. YAMAMURA

1.	Introduction	241
2.	The Binding of Antagonists	242
2.1.	Pharmacological Uses of Competitive Antagonists .	242
2.2.	Characteristics of [³ H]Antagonist Binding	242
2.3.	Cellular Localization of [³ H]Antagonist Binding ..	245
3.	The Binding of Agonists	247
3.1.	Characteristics of Agonist Binding	247
3.2.	Explanations for the Complexities of Agonist Binding	250

3.3. Comparison of Agonist Binding with Pharmacological Responses	253
4. Regulation of Muscarinic Receptors by Guanine Nucleotides	255
4.1. Introduction	255
4.2. Regulation of Agonist Binding by Guanine Nucleotides	255
4.3. Regulation of [^3H]Antagonist Binding by Guanine Nucleotides	265
5. The Influence of Sulfhydryl Reagents on Muscarinic Receptor Binding	268
6. Ionic Perturbation of Muscarinic Receptor Binding	269
7. Regulation of Antagonist Binding by Dopaminergic Agonists	270
8. Conclusion	275
9. References	276

CHAPTER 7

Benzodiazepine Receptors

CLAUS BRAESTRUP AND MOGENS NIELSEN

1. Introduction	285
2. Biochemical Characteristics of Benzodiazepine Receptor Binding	286
2.1. [^3H]Benzodiazepine Radioligands	286
2.2. Nonbenzodiazepine Radioligands	292
2.3. Binding Thermodynamics	293
3. BZ Receptor Solubilization	294
4. Occurrence of BZ Receptors	297
4.1. Brain versus Periphery	297
4.2. Neuronal Localization	299
4.3. Brain Distribution	304
4.4. Ontogenesis and Phylogenesis	308
5. Structural Selectivity of BZ Receptors	309
5.1. Benzodiazepines	309
5.2. Nonbenzodiazepine Inhibitors	322
5.3. Ineffective Agents	323
6. BZ Receptor Binding <i>in Vivo</i>	336
6.1. Methodological Considerations	336
6.2. Structural Selectivity	338
7. Multiple Brain BZ Receptors	339
8. BZ Receptors and GABA	343
8.1. Physiology and Pharmacology	343
8.2. GABAergic Influence on BZ Receptors	344

8.3.	Benzodiazepine Effects on GABA Receptors	353
8.4.	Barbiturates, Chloride Channels, and BZ Receptors	354
8.5.	Benzodiazepine Receptor/GABA Receptor/ Chloride Channel Complex	355
8.6.	Pharmacological Efficacy of BZ Receptor Ligands; Relation to GABA	357
9.	Miscellaneous Modulators	359
10.	<i>In Vivo</i> BZ Receptor Modulation	359
10.1.	Subchronic Treatment with Benzodiazepines	359
10.2.	Barbiturates	360
10.3.	Ethanol	360
10.4.	Diphenylhydantoin	360
10.5.	Seizures and Other "Stress"	361
11.	Endogenous Ligands?	361
11.1.	β -Carbolines	362
11.2.	Purines	363
11.3.	Nicotinamide	365
11.4.	Miscellaneous Agents and Extracts	366
12.	Radioreceptor Assay	366
13.	References	367

CHAPTER 8

Histamine Receptors in Brain

JACK PETER GREEN

1.	Introduction	385
2.	Classification of Histamine Receptors	386
3.	The Histamine H ₁ -Receptor	388
3.1.	The H ₁ -Receptor Characterized by Binding Studies	388
3.2.	The H ₁ -Linked Guanylate Cyclase	394
3.3.	The H ₁ -Linked Adenylate Cyclase	395
4.	The Histamine H ₂ -Receptor	396
5.	Psychotropic Drugs and Histamine Receptors	402
5.1.	Antidepressant Drugs	403
5.2.	Neuroleptic Drugs	407
5.3.	Hallucinogenic Substances	408
5.4.	Concluding Comment	410
6.	References	411

Index	421
-----------------	-----

MOLECULAR ASPECTS OF NEUROTRANSMITTER RECEPTORS: AN OVERVIEW

Solomon H. Snyder

1. INTRODUCTION

It is axiomatic that following synaptic release neurotransmitters interact with specific sites on adjacent cellular membranes. Molecular approaches to neurotransmitter receptors are surprisingly recent, with most research on brain neurotransmitters having taken place within the past 5–8 years. During this relatively brief period, biochemical studies of receptors have burgeoned so rapidly that they form the most common theme of the chapters in this volume.

Much of the research described in these chapters deals with neurotransmitter receptor binding studies. Frequently, reports dealing with receptor binding are titled “Such and Such Neurotransmitter Receptor.” There ensues discussion as to just what is meant by a neurotransmitter receptor. Some argue that binding studies do not deal with receptors at all but merely with binding sites which may not be associated with a physiological response and hence may not be functional. Accordingly, such entities do not deserve the name receptor.

Because of these controversies, it might be best to commence with some definitions. The concept of hormone or neurotransmitter receptors

Solomon H. Snyder • Department of Neuroscience, Pharmacology, and Experimental Therapeutics, and Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.

is largely a pharmacological one. Prior to the advent of molecular probes, pharmacologists measured physiological responses to drugs, hormones, and neurotransmitters, often monitoring contractions of smooth muscles. The "receptor" was that entity which was responsible for the "response." It was generally assumed that the total receptor apparatus must include a recognition site, some transducing mechanism, and an effector device. According to this view, one does not study receptors unless one investigates in each experiment all three elements. Thus, the only legitimate receptor research is that which measures smooth muscle contraction, secretion of a bodily substance, or some other physiological response.

Of course, this caricature applies only to an extreme point of view. However, it does address an important issue. In some instances, receptor recognition sites may not be linked to an effector apparatus and thus fit the designation "silent receptors." On the other hand, when we cannot detect a response associated with a receptor site, we may not be justified in concluding that there is no response but merely that we have been monitoring the wrong measure. This issue comes up in different experimental situations. For instance, the regional distribution of some neurotransmitter receptors does not parallel precisely the distribution of neuronal systems containing the transmitter. Thus, beta-adrenergic receptor binding sites are widely distributed throughout the brain and are highly concentrated in areas such as the corpus striatum which contains little or no norepinephrine (Bylund and Snyder, 1976). One may conclude either the beta-adrenergic receptor recognition sites are meaningless entities or that we are missing a subtlety of nature. For instance, perhaps there exists a hitherto unrecognized neurotransmitter other than norepinephrine which interacts with beta-receptors. Recently it has been possible to monitor by autoradiography the distribution of cholecystokinin (CCK) receptor sites using [125 I]-CCK-33, the 33 amino acid form of the peptide (Zarbin *et al.*, 1981). A number of very discrete localizations of the autoradiographically visualized grains, including discrete clusters in the optic tract and superior colliculus, differ markedly from the localization of CCK-containing neuronal systems mapped with antibodies to CCK. The rapidly accumulating evidence for multiple forms of CCK stored in distinct neuronal systems (Rehfeld, 1978) suggests that the visualized receptors are associated with neurons containing a form of CCK other than that which has been visualized in immunohistochemical studies.

It has been generally thought that the transducing element connecting neurotransmitter recognition to alterations in cellular function involves either changes in ion permeability or alterations in cyclic AMP formation. Recent evidence has greatly increased the number of possible second messenger or transducing mechanisms. Studies, especially from Axelrod's laboratory, suggest that in some instances adenylate cyclase may be a third messenger whose enhancement is provoked by an initial stimulation of

phospholipid methylation evoked by the hormone or neurotransmitter (Hirata and Axelrod, 1980). Beginning with the pioneering work of the Hokins, there has been a progressive accumulation of data linking formation of phosphatidylinositol with cholinergic, histamine, and substance P-associated synaptic activity. Alterations in calcium permeability may be important and linked to various types of messages. For instance, cyclic GMP formation is related to changes in calcium disposition. Calcium is also associated with specific binding proteins, most notably calmodulin, which in turn modulates numerous cellular responses. Calcium is also crucial for the activity of numerous enzymes, such as a protease which may be linked to glutamate receptors (Baudry and Lynch, 1980; Vargas *et al.*, 1980). Also, calcium is required for the activity of phospholipase A₂ which generates arachidonic acid, the precursor of prostaglandins which in turn mediate many receptor-associated responses.

How all these "second messengers" interact is unclear. One model holds that the rapid opening and closing of ion channels is responsible for classical excitation and inhibition in synaptic transmission. Biochemical alterations, such as changes in cyclic nucleotide, phospholipid, or prostaglandin formation may mediate slower changes. Some of these latter activities may be long-lasting "trophic" alterations involved in synaptic plasticity and other events associated with memory processes. Clearly one of the tasks of neurotransmitter research is to work out the molecular events which link receptor recognition to subsequent cellular events.

2. RECEPTOR RECOGNITION: ION AND NUCLEOTIDE REGULATION ASSOCIATED WITH "SECOND MESSENGERS"

The first biochemical approaches to receptor labeling for neurotransmitters dealt with the nicotinic cholinergic receptor in the electric organs of invertebrate fishes. These studies took advantage of the extremely high receptor content of these organs, amounting to 20% of membrane protein in some instances. Additionally, in these studies potent snake toxins were utilized which bound with high affinity and virtually irreversibly to the receptors. Such approaches could not be readily applied to the brain where receptor density in most cases is only about one-millionth by weight of brain tissue and in which unique irreversible, yet neurotransmitter-specific, toxins do not exist. Early studies using [³H]atropine and intestinal smooth muscle indicated the feasibility of labeling receptors with reversible ligands, but technical difficulties, such as low signal-noise ratio, precluded any widespread development of these limited initial studies.